Lv32
318 积分 2024-09-11 加入
Dosing and route of administration of clindamycin given in combination with rifampicin
5天前
已关闭
Dosing and route of administration of clindamycin given in combination with rifampicin
6天前
已关闭
Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology
6天前
已完结
Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs
6天前
已完结
Treatment-related adverse events of antibody drug-conjugates in clinical trials
12天前
已完结
Pooled Exposure-Response (ER) and Quantitative Benefit/Risk (B/R) Analyses Support the Approved Copanlisib Intermittent Dosing Regimen
18天前
已关闭
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio
1个月前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
1个月前
已完结
Response and Resistance to RAS Inhibition in Cancer
1个月前
已完结
Model-based meta-analysis of safety for monomethyl auristatin E-conjugated antibody drug conjugates in cancer patients
1个月前
已关闭
皖公网安备34019202002308
